Remicade (infliximab) - J&J
Humira (adalimumab) - AbbVie
Stelara (ustekinumab) - J&J
Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim
Rinvoq (upadacitinib) - AbbVie
Orofacial granulomatosis associated with Crohn's disease: clinical phenotype and response to biologics and Janus kinase inhibitor therapy in a large multi-center cohort. (PubMed, J Crohns Colitis) - Sep 23, 2026 - "OFG is associated with a distinct CD phenotype characterized by frequent UGI and perianal involvement. Advanced therapies, including anti-TNF, anti-IL23, and JAKi therapies, are effective, with evidence supporting dose optimization." 
Journal • Retrospective data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease
http://www.ncbi.nlm.nih.gov/pubmed/42768927
 
Angelica Molinillo Marin; Cameron Herbert; Christopher A Lamb; Daniel Parkinson; Esther Hullah; Gregory Young; Jeremy Sanderson; Joel Mawdsley; Laetitia Pele; Lauren Beck; Miles Parkes; Priyanka Patel; Richard Ally Speight; Robert D Lees
 
Sep 23, 2026
 
Prev Next